New cancer drug AMT-676 enters first human tests

NCT ID NCT06400485

Recruiting now Disease control Sponsor: Multitude Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior treatment. The main goals are to find a safe dose and to watch for side effects, while also checking how the drug behaves in the body and whether it shows any signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMT-676 (an antibody-drug conjugate that targets CDH17 on cancer cells and delivers a chemotherapy-like drug)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors like colorectal or gastric cancer that have stopped responding to standard therapies.
What could go wrong: This is a very early, first-in-human trial with only 24 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cabrini Hospital
RECRUITING

Melbourne, Victoria, Australia
Carolina Biooncology Institute
NOT_YET_RECRUITING

Huntersville, North Carolina, 28078, American Samoa
Fujian Provincial Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, 350014, China
Gallipoli Medical Research Foundation
RECRUITING

Greenslopes, Queensland, Australia
John Hopkins Sidney Kimmel Comprehensive Cancer Center
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19107, American Samoa
Linear Research
RECRUITING

Nedlands, Western Australia, Australia
Macquarie University Hospital
RECRUITING

Macquarie, New South wWales, Australia
SCIENTIA Clinical Research Ltd
RECRUITING

Randwick, New South Wales, Australia
Shanghai East Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200000, China
Sichuan Provincial People's Hospital
NOT_YET_RECRUITING

Chengdu, Sichuan, 610000, China
Sir Run Run Shaw Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310016, China
South Texas Accelerated Research Therapeutics (start) San Antonio
NOT_YET_RECRUITING

San Antonio, Texas, American Samoa
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.